Clinical Trial Update: MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 safety assessment of BMS-582664 in patients with advanced or metastatic solid tumors is reported; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasm

Drugs mentioned

• BMS-582664

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Tumors, Neoplasm Metastasis | Phase 1 | Status: COMPLETED